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 Endothelins (ETs) work as growth factors for fibroblastic 
growth. Keloids are clinically unpleasant scars within the 
skin that grow beyond the confines of the original wound. 
We compared the expression of ET receptors between human 
skins with hypertrophic scars and keloids, by using our quanti-
tative receptor imaging system. The ET receptor binding sites 
were distributed in skin areas anatomically corresponding 
to the epidermis, the superficial and deep dermis, and the 
vascular bed. The ETA receptor was apparently observed in 
the skin areas, whereas the ETB receptor was only slightly 
detected, as deduced from the finding that mRNA encoding 
the human ETA receptor is expressed in the fibroblast and 
the vascular bed. The ETA receptor densities of keloid and 
highly hypertrophic scar were significantly higher than those 
of normal skin and moderately and mildly hypertrophic scar. 
There seemed to be no differences in the density between 
keloid and highly hypertrophic scar. In a keloid skin we noted 
a possible existence of atypical vascular bed ETA receptor 
with a low affinity to ETA antagonist of PD151242 and 
FR139317. The ETA receptor of endogenous growth factors 
possibly play an etiological role in dysfunctions of the 
fibroblast in hypertrophic scars, and a typical ETA receptor 
may be related to the growth of keloid.
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acid residues, work as autocrine and paracrine trans-
mitters, by interacting with two receptors; ETA and 
ETB of G-protein coupling-type receptors with seven-
transmembrane domains.""-"' As ETs were originally 
isolated from cultured porcine aortic endothelial cells, 
extensive studies have been performed to clarify the 
regulatory significance in maintaining the function of 
cardiovascular-endothelial system. In addition to a role 
in modulation of vascular tone, ETs function as autocrine 
/paracrine growth factors. The peptides stimulate DNA 
synthesis of rat vascular smooth muscle cells, astrocyte, 
C6 glioma cells'4,'020.21) in collaboration with other growth 
factors such as platelet-derived growth factor and insu-
lin.') Cultured rat astrocytes proliferate and differenti-
ate through activation of their own ETB receptor.) In 
the case of human dermal fibroblasts, interestingly, the 
ETA receptor operates in the mitogenic effect on these 
cells."' 
 Takagi et al. (1994) 29,30) and Tao et al. (1995) 32) found 
that in primary culture of rabbit and bovine corneal 
epithelium ET-1 stimulated and accelerated wound clo-
sure in vivo. Keloids are clinically unpleasant scars 
within the skin that growth beyond the confines of 
the original wound, and dys- and/or hyperfunction of 
dermal fibroblasts during wound-healing seems to be 
an event related to the pathophysiology of keloids. 
Therefore, to investigate the pathophysiological signifi-
cance of ETs on wound healing process and keloid for-
mation, we compared the expression of ET receptors 
in human skins, keloid and hypertrophic scar.
Introduction
 Endothelins (ETs), family peptides of biologically 
active ET-1, ET-2 and ET-3 consisting of 21 amino
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Materials and Methods
Human skins 
 Human skins with keloid, and hypertrophic scar 
were obtained from 5 patients undergoing keloid and 
hypertrophic scar removal in university-affiliated clinics
(Table 1). Lesions were classified according to clinical 
findings into; 1) keloid (cases # 1 and # 2), 2) highly 
hypertrophic scar (case # 3), 3) moderately hypertrophic 
scar (case #4), and 4) mildly hypertrophic scar (case 
# 5). Normal parts of skins were dissected from skins 
of patients with keloid (case # 1) and also obtained from 
trimmed excess site from free flap transfer (case # 6). 
Collected tissues were immediately frozen at -30°C in dry 
ice-isopentane and stored at -80`C. Informed consent 
was obtained from each patient after the study proce-
dures had been fully explained.
Table 1. Summary of the patients
case No. sex age clinical classification 
    1 M 43 keloid 
                                 normal skin* 
    2 F 57 keloid 
    3 F 5 highly hypertrophic scar 
     4 F 21 moderately hypertrophic scar 
    5 F 38 mildly hypertrophic scar 
     6 M 64 normal skin**
*Normal skin was obtained from trimmed excess site after scar revision . 
**Normal skin was obtained from trimmed excess site after free flap tranfer .
Quantitative receptor autoradiography for ET receptors 
binding 
  Frozen, 16-pin-thick sections of human skins were cut 
on a cryostat at -20°C, thaw-mounted onto gelatin-coated 
slides and stored overnight under vacuum at 4C. Related 
tissue sections were labelled in vitro with "25I-ET-1 [non-
selective radioligand] (specific activity -81.4 TBq/mmol), 
125I-PD 151242 [ETA radioligand ] " , or 125I-IRL 1620 [ETB 
radioligand] )3"(-81.4 TBq/mmol) in 2.0 ml of incubation 
buffer, according to our method .25,34.39> Briefly, after pre-
incubation at room temperature (23°C) for 10 min in in-
cubation buffer, the sections were incubated with a fixed 
amount or increasing concentrations of radioligands, at 
4°C for 48 hr, in the presence or absence of ET receptor-
related compounds such as ET-1, ET-3, sarafotoxin S6c 
[ ETB agonist] 38' , BQ-123 [ETA antagonist]"), BQ-788 
[ETB antag-onist]12', IRL1620 [ETB agonist]31), PD151242 
[ETA antagonist] ", or FR 139317 [ETA antagonist] 2", in 
50 mM Tris-HC1 buffer, pH 7.4, containing 100 mM NaCl, 
10 mM EDTA-2Na, 1 mg/ml bacitracin, 4 pg/ml leupeptin, 
2 pg/ml chymostatin, 10 pM phosphoramidon, and 0.3% 
protease-free bovine serum albumin. After incubation, 
the slides were washed three times (1 min each) at 
4°C in 50 mM Tris-HCI buffer, pH 7.4, and rinsed quickly 
in ice-cold distilled water. Tissue sections were dried 
under a stream of cold air. The dried sections were
apposed against Hyperfilm-3H (Amersham International 
plc., UK) and the films were developed with a D19 de-
veloper (Eastman Kodak, USA) for 7 min at 4°C. 
 Quantitation of radioligands binding was made using 
our method, taking advantage of the high sensitivity of 
the computerized radioluminographic system with im-
aging plates coated with fine photostimulable phosphor 
crystals (BaF- Br:Eu2+) (Bio-imaging analyzer BAS 2000, 
Fuji Photo Film Co., Japan)." The dried sections were 
exposed to a radioluminographic imaging plate with cali-
brated 1251-standards ([ 125I ] micro-scales, Amersham). The 
values for photostimulated luminescence obtained di-
rectly from the imaging plates by the computerized 
scanning system were converted to the bound radioac-
tivity of the section and the results were expressed as 
the mean ± S.E. in fmol/mg, based on a comparison 
with standard curves for sets of standards run for each 
autoradiogram. We measured the photostimulated lu-
minescence at four spots in each area, and automatic 
computer averages were attained.
In situ hybridization for human ETA receptor mRNA 
 We confirmed the presence of ETA receptor mRNAs in 
the human skin, using our in situ hybridization method 
with cRNA probes."' ETA receptor PCR-amplified DNA 
fragments (ETA, bases 100-911) were subcloned into the 
multiple cloning site of pBluescript II SK' flanked by the 
T3 and T7 promotes. Double-labelled 35 S-cRNAs were 
synthesized from linearized plasmids using a-35S-UTP and 
a-35S-CTP (-47.73 TBq/mmol) with T7 RNA polymerase. 
The probes were alkaline-hydrolyzed to an average 
length of 350 bp. 
 Frozen, 16-,um-thick sections of the human skin adja-
cent to the sections used for quantitative receptor 
autoradiographic studies were processed for in situ hy-
bridization techniques. Briefly, related tissue sections 
were fixed in 4.0% paraformaldehyde-phosphate-buffered 
saline, digested with 10 ug/ml proteinase K for 10 min at 
37°C, and soaked for 10 min in 0.5% acetic anhydride-
0.1 M triethanolamine (pH 8.0) and 0.9% NaCl. Tissue 
sections were dehydrated through a graded series of 
ethanol, defatted in chloroform, and air-dried. Subse-
quently, the hybridization buffer, 10 mM Tris-HC1 buffer, 
pH 7.5, containing 50% deionized formamide,1 xDenhart's 
solution, 600 mM NaCI, 1.0 mM EDTA, 10% dextran sul-
fate, 0.25% sodium dodecyl sulfate, 50 mM dithiothreitol 
(DTT), 500 pg/ml tRNA, 250 pg/ml herring sperm 
DNA, and 35S-labelled cRNA probe (10' cpm/ml) was 
applied to each section, and cover-slipped tissue sections 
were incubated for 16 hr at 55°C. Slides were washed 
several times in 4 x NaCI-sodium citrate (SSC) with 10 
mM DTT to remove the cover slides and hybridization
buffer, and then incubated in 50% deionized formamide-
2 x SSC with 10 mM DTT for 30 min at 55°C, and in 
10 mM Tris-HCT buffer, pH 7.6, containing 20 ug/ml 
RNase, 500 mM NaCl, and 1.0 mM EDTA for 30 min 
at 37°C. Tissue sections were finally washed in 0.1 x 
SSC-10 mM 2-mercaptoethanol for 15 min at 55°C, and 
dehydrated through a graded series of ethanol. The 
sections were dipped into NTB-3 nuclear emulsion 
(Eastman Kodak), stored in the dark at 4°C for 30 days, 
developed with a D19 developer, then counterstained 
with hematoxylin and mounted.
Data analysis and materials 
 To determine the maximum binding capacity (Bmax), 
the dissociation constant (KD), and the inhibition con-
stant (Ki), radioligands binding data were analyzed using 
the program LIGAND (BIOSOFT, UK).17'8' Differences in 
binding parameters, KD, and Bmax were assessed by one-
way analysis of variance (ANOVA), followed by Bonferroni 
/Dunn multiple range test (StatView 4.5, Abacus Concepts, 
Inc., U.S.A.) at a p value of less than 0.05. 
  All radiolabelled compounds used here, a-35S-UTP, a-35S-
CTP, 1251-ET-1, 125I-IRL1620, and 125I-PD151242 were pur-
chased from New England Nuclear, USA, and Amersham, 
UK. BQ-123 was a gift from Banyu Pharmaceutical Co., 
Ltd., Japan, IRL 1620 was from Ciba-Geigy Japan Ltd., 
Japan, PD151242 was from Parke-Davis Pharmaceutical 
Research Division, USA., and FR139317 was from Fujisawa 
Pharmaceutical Co., Ltd., Japan. Peptides were purchased 
from Peptide Institute Co., Ltd., Japan. pBluescript II SK' 
and T7 RNA polymerase were obtained from Strategene 
Inc., USA, and Takara Shuzo Co., Ltd., Japan, respectively.
(Fig. I E) and 0.01 fmol / mg of non-specific binding 
(Fig. I J) in the dermis of normal skin. Thus, we con-
firmed that this receptor autoradiographic method cou-
pled to the radioluminographic imaging plate system 
makes feasible quantitative determinations of the ET 
receptors in the human skin, with a considerable increase 
in sensitivity. 125I-ET-1 Binding in the epidermis was irre-
placeable with large amounts of non-radioactive ET-1, 
suggesting it to be non-specific binding. 
 As shown in Fig. IA, we noted the highest density 
of 125I-ET-1 binding to the dermis of keloid, among 
human skins with highly (Fig. 113), moderately (Fig. 
IC), and mildly hypertrophic scars (Fig. ID). Taking 
note of a very low density in the dermis of normal 
skin (Fig. 1E), The amount of ET receptors expressed 
in the dermis seemed to depend upon the degree of
Results
Distribution of endothelin receptors in keloid and 
hypertrophic scar tissues 
 Under binding conditions, we observed a considerable 
amount of 125I-ET-1 [non-selective radioligand] binding 
to the human skin with a significant amount of den-
sity. Total binding and non-specific binding (Fig. 1 F 
to J) of '25I-ET-1 are evident in the left side-panel (Fig. 
1 A to E), and right side-panel (Fig. 1 F to J), respec-
tively. '25I-ET-1 binding sites were distributed in skin 
areas anatomically corresponding to the epidermis, su-
perficial and deep dermis, and vascular beds. Even with 
a low concentration (0.77 PM) of '25I-ET-1 in the incu-
bation buffer, a considerable amount of specific `25I-ET-
1 binding to the human skin tissue could be detected 
and was calculated to be 1.1 fmol/mg of total binding
Fig. 1. Evidence for the existence of ET receptor binding sites in 
skin areas of keloid (A, case #2), highly hypertrophic scar (B, 
case # 3), mederately hypertrophic scar (C, case # 4), mildly 
hypertrophic sar (D, case # 5), and normal skin (E, case # 6). 
Receptor autoradiograms were obtained at incubations of 1.7 
nM 1251-ET-1 [non-selective radioligand]. Non-specific binding 
of ET receptor binding sites (F to J, right side panel) were 
determined in the presence of 1.0 iM of labelled ET-1.
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cicatrization. " 
To characterize ET receptor binding sites, we used two ~r 
select     ive radioligands; 125I-PD151242 [ETA radioligand], 
and I-IRL1620 [ETB radioligand]. Figure 2 shows re '        125 
suits of investigation using 1251-IRL 1620, which binds , 
specifically to endothelin ETB receptor. We could not 
detect significant amounts of specific 125I-IRL1620 bind- B G 
ing to the human skin areas. -
  Contrary to 125I-IRL1620 binding, there were rich bind-
ing sites of 125I-PD 151242 [ ETA radioligand ] in the human 
skin areas; superficial and deep dermis, and vascular beds ° , 
(Fig. 3), corresponding to 125I-ET-1 binding sites. Thus, 
the ETA receptor seemed to predominantly exist in the C .... H 
human skin areas. 
 A F x~ a 
D 
                                                                                                                       low
                                                        Fig. 3. Evidence for the existence of ETA receptor binding sites 
                              
_ - in skin areas of keloid (A, case # 2), highly hypertrophic scar 
                                                      (B, case # 3), moderately hypertrophic scar (C, case # 4), mildly
                                                        hypertrophic sar (D, case # 5), and normal skin (E, case # 6).
 D~ Receptor autoradiograms were obtained at incubations of 1.0 
        ° 
nM 125I-PD151242 [ETA radioligand]. Non-specific binding of 
                                                        ETA receptor binding sites were determined in the presence
                                                    of 1.0 uM of unlabelled PD151242. 
                                                  Microscopic observation of endothelin ET receptor 
 E ., J 
                                                  Cellular distribution of the ET receptor expressed in 
                                                  the human skin areas was also investigated (Figs. 4
                4 and 5) . As shown in Fig. 4, we microscopically confirmed 
                                                 that fibroblasts richly aggregated in the superficial 
                                                 dermis of human skins with keloid (Fig. 4A and B), and 
Fig. 2. No evidence for the existence of ETB receptor binding hypertrophic scar (Fig. 4C and D). The area with a rich 
sites in skin areas of keloid (A, case #2), highly hypertrophic aggregation of fibroblasts (fibroblasts rich area) (Fig. 
scar (B, case #3), mederately hypertrophic scar (C, case #4), 4Aa and Ca) was compared with the autoradiographic 
mildly hypertrophic sar (D, case #5), and normal skin (E, localization of 1251-PD151242 binding sites (Fig . 4Ba and 
case #6). Receptor autoradiograms were obtained at incuba-
tions of 330 pM 1251-IRL1620 [ETB radioligand]. Non-specific 
binding of ETB receptor binding sites were determined in the rich layer of the dermis, suggesting that the ETA re-
presence of 1.0 uM of unlabelled IRL1620 (F to J, right side ceptor existed in fibroblasts. Similarly, belt-shaped bind-
panel). Note no differences in the density between total bind- ing sites in the deep dermis (Fig . 4Bb and Db) corre-i
ng (left side panel) and non-specific binding (right side panel). 
                                               sponded with vascular beds (Fig. 4Ab and Cb).
Fig. 4. Comparison of microscopic evidence (A and C, hema-
toxylin and eosin) on fibroblastic aggregations (a) and vas-
cular beds-distribution (b) with receptor autoradiographic lo-
calization of ETA receptor binding sites (B and D) in the 
superficial dermis of keloid (A and B, case #2) and highly 
hypertrophic scar (C and D, case #3). The squares "a" and 
"b" of the pa
nels B and D are compartible to "a" and "b" of 
the panels A and C.
 We confirmed the cellular expression of ETA recep-
tor mRNA in the human skin, using our in situ hy-
bridization method with cRNA probe and an emulsion 
autoradiographic technique (Fig. 5). 35S-labelled cRNA 
probe derived from the ETA receptor cDNA specifically 
hybridized to the human skin section (Fig. 5A and B), 
as evidenced by no significant hybridization signals in 
parallel experiments performed under conditions with 
the same probe in the presence of a 50-fold excess of 
unlabelled probes (Fig. 5C and D). Light microscopic 
autoradiograms revealed that silver grains of 35S-ETA 
cRNA were discretely distributed throughout the skin 
areas. There were many silver grains of 35S-ETA cRNA in 
vascular beds (Fig. 5A), and also the silver grains were 
concentrated in spotty areas with a cluster of fibroblasts 
(Fig. 513).
Characterization and Quantitation of ET receptor in human 
skin 
 Related, 16-,am-thick sections were incubated in the 
presence of increasing and nine different concentra-
tions of '25I-ET-1, ranging from 0.77 pM to 1.7 nM, in 
the absence (total binding) or presence of 1.0 tM ET-1 
(non-specific binding) (Fig. 6). In 125I-ET-1 saturation
Fig. 5. Cellular localization of the expression of mRNA en-
coding ETA receptor in vascular beds (A) and fibroblasts (B) 
of human skins with keloid (case #2). Silver grains of 35S-
ETA cRNA are heterogeneously distributed throughout the 
human skin areas. Non-specific signals (C and D) were deter-
mined at competition of 35S-labelled cRNA probes with a 50-
fold excess of unlabelled ETA cRNA.
Fig. 6. A saturation binding study with increasing concentra-
tions (0.77 pM to 1.7 nM) of 125I-ET-1 (left side panel) carried 
out in the human skin sections of keloid (case # 2, open cir-
cles) and of highly hypertrophic scar (case # 3, closed circle). 
Scatchard plots (right side panel) were obtained by '25I-ET-1 
saturation binding data, analyzed using the program LIGAND.
binding experiments done on use of consecutive tissue 
sections obtained from patient with keloid (case # 1 of 
Table 1, open circles), and hypertrophic scar (case # 3, 
closed circles), specific '25I-ET-1 binding to the superfi-
cial dermis of keloid was saturable (Fig. 6, left side
panel), and Scatchard analysis of the data obtained from 
a LIGAND computer program gave a straight line (Fig. 
6, right side panel), thereby indicating that '25I-ET-1 
binds to a single population of the ET receptor bind-
ing sites. 
  The KD, and Bmax values of the ETA receptor in the 
human skin areas; were listed in Tables 2 and 3. As 
shown, the KDS, a parameter of ligand-binding affinity, 
were of the same order of magnitude, from 36 pM of 
the minimum value to 86 pM of the maximum, with 
the exception of 125 pM in the vascular beds of case 
#2, a finding which supports the idea that a single 
and homogenous population of the ETA receptor exists 
in the human skin areas, even in hypertrophic scar 
and keloid with fibroblastic proliferation. 
 Taking note of the present data that we detected a 
single and homogenous populations of the ETA recep-
tor (Table 2), and magnitude of the number of ETA re-
ceptor (expressed as Bmax), we divided the Bmax values 
of the receptor in the superficial and deep dermis into 
four groups; a) keloid, b) highly hypertrophic scar, c) 
moderately and mildly hypertrophic scar, d) normal 
skin. Then, we compared statistically the apparent Bmax 
calculated from values listed in Table 3, among four 
groups, and found a significant difference in the Bmax 
value between keloid, a group of moderately and mildly 
hypertrophic scar, and normal skin [keloid, 19.5 ± 2.3 
fmol/kga (mean ± S.E.M., n = 4); moderately and mildly 
hypertrophic scar hypertrophic scar, 6.5 ± 0.9 fmol/mgc 
(n = 4); normal skins, 2.7 ± 0.4 fmol/mgd (n = 4); a > 
c, p < 0.0001; a > d, p < 0.0001) ]. Thus, the number of 
the fibroblastic ETA receptor in keloid was signifi-
cantly higher than normal skin and low grade (moder-
ately and mildly) hypertrophic scar. 
 In contrast, we failed to detect significant differences 
between keloida and highly hypertrophic scarb [12.9 
± 5.2 fmol / mg (n = 2)]. Furthermore, as shown in
Table 2. Binding parameter; dissociation constant (KD) ob-
tained from 125I-ET-1 saturation binding experiments done on 
use of consecutive human skin tissue sections
                              KD (PM) 
                     superficial dermis deep dermis vascular beds in dermis 
keloid (case 1) 56 45 53 
keloid (case 2) 48 26 125 
highly hypertrophic scar (case 3) 43 68 23 
moderately hypertrophic scar (case 4) 36 83 65 
mildly hypertrophic scar (case 5) 75 78 41 
normal skin (case 1) 86 38 78 
normal skin (case 6) 53 46 39
Dissociation constant (KD) was calculated by the program LIGAND. 
Increasing concentrations (0.77 pM to 1.7 nM) of '251-ET-1 were used.
Table 3. Binding parameter; maximum binding capacity (Bmax) 
obtained from 125I-ET-1 saturation binding experiments done 
on use of consecutive human skin tissue sections
                                 Bmax (fmol/mg) 
                      superficial dermis deep dermis vascular beds in dermis 
keloid (case 1) 19a 14a 10 
keloid (case 2) 25a 20a 18 
highly hypertrophic scar (case 3) 18b 7.7b 12 
moderately hypertrophic scar (case 4) 8.7c 7.Oc 16 
mildly hypertrophic scar (case 5) 4.6c 5.6c 8 
normal skin (case 1) 3.6d 2.Od 13 
normal skin (case 6) 2.3d 2.9d 10
Maximum binding capacity (Bmax) was calculated by the program 
LIGAND. Increasing concentrations (0.77 pM to 1.7 nM) of 1251-ET-1 
were used. Statistical differences were observed bewteen Bmax values 
(mean ± S.E.) of keloida [19.5 ± 2.3 fmol/kg (n=4)], moderately and 
mildly hypertrophic scar' [6.5 ± 0.9 fmol/mg (n=4)] and normal skinsd 
[2.7 ± 0.4 fmol/mg (n=4)]; a>c, p<0.0001; a>d, p<0.0001, whereas 
no difference was detected between keloida and highly hypertrophic 
scarb [12.9 ± 5.2 fmol/mg (n=2)].
Table 3, it seemed likely that there was no difference 
in the number of the vascular bed ETA receptor among 
between keloid, hypertrophic scar, and normal skin.
A possible heterogeneity of the ETA receptor expressed in 
the vascular beds of keloid 
 To further characterize the ETA receptor, we did 
competitive ligand-binding experiments with a fixed 
amount (60 PM) of '25I-ET-1, in that effects of increas-
ing concentrations of ET-1 and ETA receptor-related 
compounds such as BQ-123, PD151242, and FR193317 
on specific 125I-ET-1 binding were examined (Tables 4 
and 5, Fig. 6). `25I-ET-1 binding to the superficial dermis 
was competitively displaced by incubation in the pres-
ence of increasing concentrations of ET-1 with K; at 
values ranging from 57 pM to 120 pM (Table 4). BQ-
123, ETA receptor antagonist, was also a potent displacer 
for specific 1251-ET-1 bindings to the superficial dermis. 
Although PD 151242 and FR 139317 had a much weak 
potency in displacing binding, compared to the potency 
of BQ-123, the both ETA antagonists significantly dis-
placed binding. We observed the same potencies of ET-1, 
BQ-123, PD151242, and FR139317 to displace 125I-ET-1 
binding to the superficial dermis of all cases examined. 
 In the case of vascular bed ETA receptor (Fig. 6, Table 
6), BQ-123 and ET-1 equipotently displaced 125I-ET-1 
binding to the vascular ETA receptor in all cases exam-
ined, however, we noted a very phenomenal finding in the 
data obtained from the competition study with PD 151242 
and FR 139317 in the vascular bed ETA receptor of keloid
Table 4. Binding parameter; inhibition constant (K,) of ETA 
receptor-related compounds in ET receptor binding sites in the 
superficial dermis (fibroblast rich layer) obtained from 125I-
ET-1 competition binding experiments
                                   K, (pM) 
                         ET-1 BQ-123 PD151242 FR139317 
keloid (case 1) 120 600 2700 530 
keloid (case 2) 57 330 2400 410 
highly hypertrophic scar (case 3) 120 600 3300 380 
moderately hypertrophic scar (case 4) 100 490 1500 400 
mildly hypertrophic scar (case 5) 76 610 2600 650 
normal skin (case 1) 68 360 3100 830 
normal skin (case 6) 98 420 2800 900
Inhibition constant (K,) was calculated by the program LIGAND. A 
fixed amount (60 pM) of 125I-ET-1 was used
(case 2). As shown in the autoradiograms of Fig. 6, 125I-
ET-1 binding images of the keloid (case 2) vascular 
bed obtained by displacements of PD151242 and 
FR 139317 at the concentrations of 0.1 nM ("-10" in 
the figure and an arrow) and 1.0 mM ("-6" and an 
arrow) were seen more clearly, than those of the nor-
mal skin. In fact, the K, of PD 151242 and FR 139317 
were calculated to be 31 nM and 7.8 nM, respectively, 
values which are ten times as large as hypertrophic 
keloid and normal skin (Table 5). The case # 1 of keloid 
had the same potencies of PD 151242 and FR 139317 as 
hypertrophic scars and normal skins. Thus, Among 
two cases of keloid, the case # 2 had a unique binding 
profile of PD151242 and FR139317. A different type of 
the ETA receptor, atypical receptor, may be expressed 
in the vascular bed of keloid.
Table 5. Binding parameter; inhibition constant (K,) of ETA 
receptor-related compounds in ET receptor binding sites in 
the vascular beds obtained from 125I-ET-1 competition binding 
Pxnprimentc
                                  K1 (pM) 
                         ET-1 BQ-123 PD151242 FR139317 
keloid (case 1) 210 1300 3700 980 
keloid (case 2) 67 410 31000a 7800b 
highly hypertrophic scar (case 3) 41 250 3800 830 
moderately hypertrophic scar (case 4) 170 1600 1700 770 
mildly hypertrophic scar (case 5) 170 1100 1300 780 
normal skin (case 1) 120 1000 2100 640 
normal skin (case 6) 89 600 3600 800
Inhibition constant (K,) was calculated by the program LIGAND A 
fixed amount (60 pM) of 125I-ET-1 was used. a, bNote very high mag-
nitude of K, values in the vascular bed ETA receptor of keloid (case
Fig. 7. Receptor autoradiographic evidences of a possible ex-
istence of atypical ETA receptor in the vascular bed of keloid 
(case #2). The autoradiograms were obtained from competi-
tion binding studies at incubations of 60 pM of 125I-ET-1 in 
the absence ("0") and presence of 0.1 nM ("-9") and 1.0 mM 
("-6") of FR139317 and PD 151242. Arrows indicate the ETA 
receptor binding sites. Note the findings that in the presence 
of 1.0 u M ("-6") of FR 139317 and PD 151242, the binding sites 
cannot be detected in the autoradiograms of normal skins, 
whereas more clearly seen in keloids, as indicated by arrows.
Discussion
 The findings presented here are summarized, as fol-
lows; 1) The ETA receptor was found to be overexpressed 
on fibroblasts in the dermis and on vascular beds of 
human skins with all grades (keloid, highly hypertrophic 
scar, moderately hypertrophic scar, mildly hypertrophic 
scar and normal skin). 2) No significant amounts of 
the ETB receptor could be detected in all human skins 
examined here. 3) The ETA receptor densities of keloid 
and highly hypertrophic scar were significantly higher 
than those of normal skin and moderately and mildly 
hypertrophic scar. There seemed to be no differences 
in the density between keloid and highly hypertrophic 
scar. 4) We noted a possible existence of atypical ETA 
receptor with a low affinity to ETA antagonist of 
PD 151242 and FR 139317 in the vascular bed of keloid. 
 Biological active peptide / growth factors such as 
angiotensin II and IGF-1 are thought to participate in 
wound healing process.""' In this study, we found a 
possible role of ETs, endogenous biological active pep-
tides, in the formation of hypertrophic scar and keloid. 
This is apparently the first demonstrations and charac-
terization of the ETA receptor expressed in human skin
areas with keloid and hypertrophic scar. The affinity 
of the ETA receptor binding sites for '25I-ET-1, exhib-
ited as KD (36 pM to 86 pM) obtained here, is in 
agreement with reported values of the ETA receptor. 21.34,35, 
As reported by Lawrence et al. (1995)16', ETs in the 
skin areas have been thought to regulates cutaneous 
blood flow, the present finding sheds some light on 
the new role of endothelins within skin. Taking together 
with the present finding of the expression of ETA mRNA 
in fibroblasts and vascular beds of the human skin areas, 
our results suggest a potential pathophysiological role of 
ETs during wound healing process and scar formation. 
  As ETs exerts the mitogenic effects to cultured human 
dermal fibroblasts through the ETA receptor13', of par-
ticular interest is our present finding that amounts of 
fibroblastic ETA receptor expressed in hypertrophic scar 
were closely related to the degree of severity in scar 
formation. This may mean that an increase in the number 
of ETA receptor depends on fibroblastic aggregation. 
Taking note of the present data that the number of ETA 
receptor in keloid dermis was equivalent to that in highly 
hypertrophic scar, as the both have the same density 
of fibroblastic proliferation, it seems likely that there are 
no changes in the expression amount of ETA receptor in 
one fibroblast aggregating in scar formation. Therefore, 
we tentatively conclude that an excessive proliferation 
of fibroblasts, an etiological factor in scar formation is 
due to the overexpression of the ETA receptor. In fact, 
Kikuchi et al. (1995) 13' reported that down-regulation of 
the ETA receptor decreases cell-growth of fibroblasts 
isolated from patients with scleroderma, a disease with 
fibroblastic hypofunction. 
 In addition to fibroblastic hyperfunction, dysfunctions 
of these cells are thought to participate in keloid forma-
tion as an etiological factor.'-") Fibroblasts isolated from 
keloid de novo produce TGF-/9, a growth factor func-
tionally linked to the over-expression of procollagen type 
I mRNAS' In the present study, we could not find an 
apparent difference in the receptor density between 
skin areas with fibroblastic aggregations of highly 
hypertrophic scar and keloid. Pathophysiological roles 
of ETs remain to be elucidated. As the ETA receptor 
regulates gene expression of other biologically active 
peptides via multiple G protein-linked pathways") and 
ET stimulates collagen synthesis"' , a collaboration 
mechanism between ET and growth factors may be 
operative in keloid formation.",") 
 Of two cases of keloid, in one keloid (case # 2) we 
detected a candidate of atypical ETA receptor in the 
vascular bed, with a very low binding-affinity for two 
ETA antagonists, PD 151242 and FR 139317. Dashwood 
et al. (1994)6' found the same receptor of heterogene-
ity with a low affinity of FR139317 in regions of
neovascularization of atherosclerotic human coronary 
artery (46). The present concept is that there are only 
two cDNA clones encoding the mammalian ETA and 
the ETB receptor 2,23,40)' however, accumulating evidence 
revealed functional subtypes of ET receptors which do 
not fit the present criteria for ETA and ETB receptors, 
as mainly deduced from pharmacological potencies of 
ET-1 and ET receptor-related compounds.") Also, in the 
case of the ETB receptor system, a novel ETB receptor 
splice variant with a short peptide structure at the 
carboxyl-terminal region was identified from a human 
placental cDNA library. This alternatively splicing vari-
ant of a single gene is functionally distinct from the ETB 
receptor, lacking in activating intracellular signaling.") 
Although no data are available on the ETA receptor splice 
variant, as the unique binding profile for ETA antago-
nist (FR 139317) in vascular beds was detected in prolif-
erative tissues such as keloid and region with neovacula-
rization, the possibility that an atypical ETA receptor 
is expressed during wound healing process and exerts 
tumorigenic neoangiogenesis or microcirculatory dis-
turbances to develop keloid would have to be consid-
ered. Thus, the present finding on the possible exis-
tence of atypical ETA receptor in the vascular bed of 
keloid shed some light on the pathophysiological role 
of ETs in keloid formation. 
 In summary, we obtained what seems to be the first 
evidence that fibroblasts with the ETA receptor partici-
pate in wound healing process and scar formation. 
Experimentally therapeutic approaches with newly 
synthesized antagonists for ETA receptor would have 
to be designed. The present finding on the possible ex-
istence of an atypical ETA receptor in the vascular 
beds of keloid seems to be pertinent to the role of ETs 
in the etiology of keloid.
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